Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1674)	4/20/2006 1:27:34 PM
From: Jibacoa	Respond to of 3722

ZONA Is making a 52 wks. H in spite of its larger loss for the 4thQ & the EL for 2006 around $2.80/shr vs. $0.80/shr in 2005. But the revenues have been better in the last 3Qs & the insiders may know something since they have been doing some buying. <g> ZONA has had a 144% increase in its R&D and in Feb. reported good results on an open label trial of its Androval & in Mar. it also announced that it got the green light in Europe to start its PII of Proellex for endometriosis. The stock is up 10.8% today. bigcharts.marketwatch.com ZONA has also some plans to change its name.<g> The stock has done OK in the last year.<g> bigcharts.marketwatch.com But it is still below its pre BB level, when it wanted to compete with PFE on ED prior to Viagra's approval.<g> bigcharts.marketwatch.com Bernard